301263 Guangdong Taienkang Pharmaceutical
- 13.75
- +0.12+0.88%
Guangdong Taienkang Pharmaceutical News
Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) Price In Tune With Earnings
Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) price-to-earnings (or "P/E") ratio of 38.3x might make it look like a sell right now compared to the market in China, where around half of
Taienkang (301263.SZ): Subsidiary obtained montelukast sodium granule drug registration certificate
Gelonghui May 27丨Taienkang (301263.SZ) announced that Shandong Huabo Kaisheng Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for montelukast sodium granules issued by the State Drug Administration. Montelukast sodium is a highly selective leukotriene receptor antagonist. By blocking this receptor, it acts by inhibiting leukotriene-mediated reactions, and can inhibit a range of leukotriene-mediated respiratory reactions. On July 26, 2002, MSD first launched montelukast sodium granules in the US. The trade name is SINGULAIR, and the specification is 0.5 g: 4 mg (with
Taienkang (301263.SZ): 2023 equity distribution, 10 distributions of 3 yuan, share registration date May 22
Gelonghui, May 15 | Taienkang (301263.SZ) announced that the company's 2023 equity distribution plan is to distribute RMB 3.000000 in cash (tax included) to all shareholders for every 10 shares based on the company's current total share capital excluding 423,512,382 shares after 1,985,118 shares have been repurchased. The share registration date for this equity distribution is May 22, 2024, and the ex-dividend date is May 23, 2024.
Guangdong Taienkang Pharmaceutical's (SZSE:301263) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) recent weak earnings report didn't cause a big stock movement. However, we believe that investors should be aware of some underlying facto
Taienkang (301263.SZ): Application for registration and marketing license for the domestic production of methimazole tablets was accepted
Zhitong Finance App News, Taienkang (301263.SZ) announced that Shandong Huabo Kaisheng Biotechnology Co., Ltd. (“Huabo Kaisheng”), a wholly-owned subsidiary of the company, recently received the “Notice of Acceptance” of the application for registration and marketing of drugs produced domestically by methimazole tablets issued by the State Drug Administration. According to the announcement, methimazole is an imidazole antithyroid drug. By inhibiting the activity of thyroid peroxidase (TPO), a key enzyme in the thyroid gland, it blocks the absorption of the coupling of iodide and tyrosine in the thyroid gland, and hinders the synthesis of thyroid T4 and triiodothyronine T3. A
Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) Stock Is Going Strong: Have Financials A Role To Play?
Guangdong Taienkang Pharmaceutical (SZSE:301263) has had a great run on the share market with its stock up by a significant 6.6% over the last week. We wonder if and what role the company's financia
Taienkang (301263.SZ) announced its 2023 annual results, with net profit of 160 million yuan, a decrease of 8.26%
Taienkang (301263.SZ) released its 2023 annual report. The company's revenue was 761 million yuan,...
Taienkang (301263.SZ): Application for marketing license for topical hair loss treatment “minoxidil liniment” accepted
Taienkang (301263.SZ) announced that Shandong Huabo Kaisheng Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, recently...
Huabo Jingcheng, the majority shareholder of Taienkang (301263.SZ), terminated its holdings reduction early and reduced its holdings by a total of 10.324,500 shares
According to the Zhitong Finance App, Taienkang (301263.SZ) announced that Huabo, a shareholder holding more than 5% of the company's shares, sincerely decided to terminate the holdings reduction plan early, reducing the company's holdings by a total of 10.324,500 shares.
Taienkang (301263.SZ): Proposed 2024 employee stock ownership plan with a total funding limit of 80 million yuan
Gelonghui, March 27 | Taienkang (301263.SZ) announced the 2024 employee stock ownership plan (draft). The maximum amount of capital to be raised in the employee stock ownership plan is 80 million yuan. Using “shares” as the subscription unit, each share is 1.00 yuan, of which the ratio of financing capital to own capital is not more than 1:1. According to the estimate of the closing price of the company's stock at 13.43 yuan/share on the day before the announcement of the employee's shareholding plan, the employee's shareholding plan did not exceed 5.956,800 shares, accounting for approximately 1 of the company's total share capital of 425.495 million shares on the day the employee's draft shareholding plan was announced.
We Think Guangdong Taienkang Pharmaceutical (SZSE:301263) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet wh
Taienkang (301263.SZ): Application for licensing registration and marketing of nimodipine injections accepted
Zhitong Finance App News, Taienkang (301263.SZ) announced that Shandong Huabo Kaisheng Biotechnology Co., Ltd. (“Huabo Kaisheng”), a wholly-owned subsidiary of the company, recently received the “Notice of Acceptance” for the registration and marketing license application for drugs produced domestically for nimodipine injections issued by the State Drug Administration. The State Drug Administration examined the drug registration and marketing license application for the above drugs and decided to accept it. According to the announcement, Nimodipine (Nimodipine) is a 1,4-dihydropyridine calcium antagonist that selectively acts on cerebrovascular smooth muscle and causes cerebral arterial vascular smooth muscle to relax.
Taienkang (301263.SZ): Huabo Kaisheng's pilocarpine hydrochloride eye drops obtained a drug clinical trial approval notice
Gelonghui, March 1 | Taienkang (301263.SZ) announced that Shandong Huabo Kaisheng Biotechnology Co., Ltd. (“Huabo Kaisheng”), a wholly-owned subsidiary of the company, recently received a drug clinical trial approval notice issued by the State Drug Administration and agreed to the application for clinical trials of pilocarpine hydrochloride eye drops submitted by Huabo Kaisheng. Pilocarpine hydrochloride is an M-choline receptor agonist that can activate muscarinic receptors in smooth muscle (such as iris sphincter and ciliary muscle). Through contraction of the iris sphincter muscle, the pupil contracts to increase depth of focus, improve near-central vision, and maintain pupil response to light.
Taienkang (301263.SZ) subsidiary's application for drug registration of vardenafil hydrochloride tablets was accepted
Zhitong Finance App News, Taienkang (301263.SZ) announced that Shandong Huabo Kaisheng Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Notice of Acceptance” issued by the State Drug Administration (“State Drug Administration”) for licensing registration and marketing of drugs produced domestically produced in the domestic production of vardenafil hydrochloride tablets. According to the announcement, vardenafil hydrochloride is a type 5 phosphodiesterase (PDE-5) inhibitor, mainly used to treat male erectile dysfunction (ED). The original drug Levitra was developed by Bayer and first approved in the European Union in 2003, then successively in the US, Japan, Canada, and China
Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) Market Cap up CN¥464m Last Week, Benefiting Both Retail Investors Who Own 38% as Well as Insiders
Key Insights Significant control over Guangdong Taienkang Pharmaceutical by retail investors implies that the general public has more power to influence management and governance-related decisions A
Taienkang (301263.SZ) Proposes Employee Stock Ownership Plan
Taienkang (301263.SZ) issued an announcement. The company plans to introduce an employee stock ownership plan. The regulations of the current employee stock ownership plan...
Taienkang (301263.SZ): Some directors and executives completed an increase in holdings at a cost of 176.714 million yuan
Taienkang (301263.SZ) announced that as of the disclosure date of the announcement, Chen Chun, director and deputy general manager of the company, directors...
A Look At The Intrinsic Value Of Guangdong Taienkang Pharmaceutical Co., Ltd. (SZSE:301263)
Key Insights Using the Dividend Discount Model, Guangdong Taienkang Pharmaceutical fair value estimate is CN¥14.93 Current share price of CN¥14.93 suggests Guangdong Taienkang Pharmaceutical is pote
Taienkang (301263.SZ): A total cost of 389.869 million yuan to buy back 1.9851 million shares
Gelonghui, January 2, 丨 Taienkang (301263.SZ) announced that as of December 31, 2023, the company had repurchased a total of 19851.18 million shares through the Shenzhen Stock Exchange trading system, accounting for 0.4665% of the company's total share capital. The highest price of the repurchase transaction was 20.12 yuan/share, the lowest price was 18.56 yuan/share, and the total amount of capital paid was RMB 389.869 million (excluding transaction fees).
Cautious Investors Not Rewarding Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) Performance Completely
There wouldn't be many who think Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) price-to-earnings (or "P/E") ratio of 37.1x is worth a mention when the median P/E in China is similar at
Analysis
Price Target
No Data
